Observational studyBMC infectious diseases2026
Effectiveness of conventional antimicrobial agents against carbapenem resistant non-carbapenem β-lactams susceptible Pseudomonas aeruginosa infection in critically ill patients: a multicentre retrospective study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem resistant non-carbapenem β-lactam susceptible (CRBS) Pseudomonas aeruginosa (PA) is a unique phenotype of carbapenem-resistant Pseudomonas aeruginosa (CRPA). While guidelines suggest using conventional β-lactams, clinical evidence supporting their effectiveness in critically ill patients remains limited. This study evaluated the associations of conventional antimicrobial agents with clinical outcomes in CRBS PA infections in the intensive care unit (ICU).
methodsThis multicentre retrospective cohort study included 178 patients with CRPA-associated pneumonia or bloodstream infections, comprising 119 patients with CRBS PA and 59 patients with carbapenem-resistant non-carbapenem β-lactam resistant (CRBR) PA. Patient outcomes were compared between phenotypes. The primary endpoint was to evaluate the associations between specific antimicrobial agents and clinical outcomes in CRBS PA infections, using multivariable stepwise logistic regression analyses for in-hospital mortality, day-28 mortality, day-28 clinical failure, and day-28 microbiological eradication.
resultsThe CRBS PA group demonstrated significantly lower clinical failure rates compared to the CRBR PA group (45.4% vs. 62.7%, p = 0.034), suggesting potential clinical relevance of this phenotype. In the multivariable analysis of CRBS PA infections, treatment with piperacillin-tazobactam (OR: 0.52, p = 0.03) and ceftazidime (OR: 0.27, p = 0.01) was independently associated with lower in-hospital mortality. Levofloxacin was also associated with lower in-hospital mortality (OR: 0.40, p = 0.01), lower day-28 clinical failure, and higher day-28 microbiological eradication rates (OR: 4.87, p = 0.02), although this finding should be interpreted separately from the β-lactam-based CRBS phenotype.
conclusionsThis study suggests that piperacillin-tazobactam, ceftazidime, and levofloxacin may be reasonable definitive treatment options for critically ill patients with CRBS PA infections. These findings support the consideration of carbapenem-sparing approaches in this specific CRPA phenotype, in line with current therapeutic guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.